YCBD

CIN assigns cbdMD a Neutral rating, supported by a composite score in the upper 40s and low conviction of one out of five. Fundamentals is the strongest pillar, scoring in the low 60s on revenue growth and gross-margin strength. Regulatory contributes a score near 50, reflecting a balanced jurisdiction posture and no recorded enforcement hits, offset by weak filing cadence. Market performance scores 40 because institutional pricing feeds provide no current quote, limiting evidence of price discovery and investor sponsorship. Editorial scores 30, with no recent newsroom or brief activity to reinforce the investment narrative.

Licensed fundamentals data show year-over-year revenue growth of nearly 19%, while gross margin approaches 60%, giving cbdMD a credible commercial base. That strength does not extend through the income statement: operating margin remains negative at roughly 14%, EBITDA records a loss of approximately $1.6 million, and net income records a loss near $2.7 million. The cash-burn ratio of about 0.20 and a cash-runway subscore below 50 reinforce the stretched financial condition; positive top-line momentum has not delivered operating self-sufficiency. Primary regulatory filings also provide no dated latest filing in the dataset. The cadence subscore of 25 therefore constrains the otherwise stronger regulatory contribution, even as the absence of recent events and enforcement hits supports the pillar.

The forward catalyst rests squarely on fundamentals, the only pillar above 60. Sustained revenue expansion paired with the existing gross-margin profile creates a direct route toward lower operating losses, improved EBITDA, and better cash conversion. Progress on that route would strengthen the composite even without immediate support from market or editorial signals, while another period of negative operating leverage would preserve the Neutral band. The single most important signal to watch is whether nearly 19% revenue growth converts into a materially narrower negative operating margin.